While mCII259–273/DR4-IE nanoparticles exhibited no therapeutic efficacy, hMOG97–108/DR4-IE nanoparticles effectively mitigated EAE to a level comparable to that of the positive control.490 Therefore, pMHC-based nanomedicines represent a new class of therapeutics for autoimmune diseases that are capable of resolving complex autoimmune responses in a disease- and organ-specific manner without compromising systemic immunity. Here, TNFRSF10A is linked to autoimmune disease.